Redeye provides an update in relation to Enzymatica’s Q3 2023 report. The report did not meet our expectations, even if EBIT came in better than anticipated. We are concerned about the issues with STADA and believe it will affect future sales. Moreover, we made some estimate changes, increased our WACC, and added capital raising into our model. These changes render an updated fair value range, including a new base case of SEK6 (6.5).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Enzymatica Q3 - The STADA partnership creating concerns about the future

© Modular Finance, source Nordic Press Releases